Cosmos Health Inc. · NASDAQ:COSM
Cosmos Health — Investor Presentation (December 2022)
31 slides from Cosmos Health's investor presentation, December 2022
Slide 1: Cosmos Health Inc. Company Presentation December 2022
COSMOS HEALTH INC. (NASDAQ: COSM) DECEMBER 2022 COMPANY PRESENTATION
Slide 2: Disclaimer
DISCLAIMER This presentation is not an offer to sell securities, nor is it a solicitation of an offer to buy securities in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation, or which would require any reg
Slide 3: Our Philosophy
OUR PHILOSOPHY Committed to serve healthcare with passion and innovation in order to improve people’s lives. 3
Slide 4: Cosmos Health: An International Healthcare Group
COSMOS HEALTH AN INTERNATIONAL HEALTHCARE GROUP Who we are What we do How we do it • We are Cosmos Health, an • We develop and distribute our own • We prioritize our customers’ needs, international healthcare group proprietary line of nutraceuticals as focusing on the latest scientific listed in Nas
Slide 5: Cosmos Group Overview
COSMOS GROUP OVERVIEW • Corporate Office in the Chicago • Office area of 850m2, fully • State of the art GDP warehouse, • Warehouse area of 400m2, Board of Trade Building,141 West equipped & air-conditioned of total surface area of 2,900m2, licensed under GDP with Jackson Blvd, Chicago, Illinois. •
Slide 6: Our Business Model
OUR BUSINESS MODEL Nutraceuticals Pharmaceuticals Healthcare Distribution • “Sky Premium Life” and “Mediterranation” • Exclusivity on medicine licenses of fast-moving • Direct distribution and sales of pharmaceuticals, high-end brands of premium nutraceuticals product codes medical devices, generics
Slide 7: Market Overview
MARKET OVERVIEW Nutraceuticals Pharmaceuticals Healthcare Distribution ❖ Global Nutraceuticals Market was valued at ❖ The Global Pharmaceuticals Market is expected to ❖ Global Healthcare Distribution Market was valued $455bn in 2021 and is expected to reach grow from $1,455bn in 2021 to $1,587 in 20
Slide 8: Our Strategy
OUR STRATEGY Our focus is high We use our extended margin nutraceuticals network to gain and R&D efforts to access to new develop IP products markets and business segments. Diversification allows us to exploit new opportunities and synergies while minimizing risk. 8
Slide 9: Achieving More…
ACHIEVING MORE… … in Nutraceuticals … in Pharmaceuticals … in Healthcare Distribution ❖ Pioneer (new proprietary line “Mediterranation”, ❖ Distribution synergies (capitalize on our long- ❖ Well-positioned (long-lasting relationships, up- Mediterranean & Greek herbs accessible to lasting relationship
Slide 10: Our Brands & Products
OUR BRANDS & PRODUCTS Nutraceuticals Advanced Formulations R&D BASED 10
Slide 11: Sky Premium Life nutritional supplements
Nothing can replace a healthy diet based on real clean food, but sometimes we need a little help. Sky Premium Life®, combining carefully selected raw materials, production based on strict pharmaceutical standards and GMP (Good Manufacturing Practices) protocols, as well as the scientifically based s
Slide 12: Mediterranation line
The Mediterranation® line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean. These unique formulations contain a proprietary blend of vitamins and minerals and are made with the
Slide 13: Melatonin
Prepared with Nanoemulsification Technology, achieving MELATONIN 240% greater and 630% faster absorption compared to The wise choice for a good sleep. the tablets, within the first 5 minutes after sublingual administration. Melatonin is recommended for the treatment of insomnia and bioregulation (je
Slide 14: Otikon: We Don't Close Our Ears
❖ The only completely herbal preparation for the treatment of symptoms otitis media and WE DON’T CLOSE OUR EARS… otitis externa. ❖ The only herbal preparation with Otikon is prepared using documented action through clinical studies. herbal ingredients ❖ Effective in ear infections of viral origin. w
Slide 15: Relief of pain & irritation in the throat
Relief of pain & irritation in the throat ❖ Unique combination of lidocaine & chlorhexidine ❖ Maximum antiseptic effect thanks to chlorhexidine & ethanol ❖ Local anesthetic effect thanks to lidocaine ❖ Easy absorption from the oral & pharyngeal mucosa ❖ Sugar free ❖ Safe for use by diabetics 15
Slide 16: Enhances Male Fertility
i ENHANCES MALE FERTILITY ICOSMOS HEALTH GLOBAL HEALTHCARE GROUP
Slide 17: Research & Development: Cloudpharm partnership
RESEARCH & DEVELOPMENT Cosmos Health Inc. announced on June 30, 2022, a strategic partnership with Cloudpharm P.C., a bio-pharmaceutical R&D company focused on the discovery GLOBAL HUMAN MICROBIOME MARKET of bioactive compounds with an emphasis on natural products, with the aim of developing new med
Slide 18: Bone-Vio: Bone Remodeling Through the Microbiome
BONE –VIO ® BONE REMODELING THROUGH THE MICROBIOME Prebiotic formulated for bone health ❖ Snatural® derived – formulation ❖ Enhanced Ca++ absorption through the microbiome 18
Slide 19: Osteome: Healthy Bone Through the Microbiome
OSTEOME ® HEALTHY BONE THROUGH THE MICROBIOME ❖ Develop a novel dietary supplement for osteoporosis, activating the gut microbiome. The selection of bioactive will take place through in vitro and in silico studies focusing on their interaction with pathways that regulate the activity of osteoclasts
Slide 20: Lightia: A New Path to Treat Obesity
LIGHTIA ® A NEW PATH TO TREAT OBESITY ❖ Lightia® utilizes a next generation safe and convenient treatment option to manage weight to adults with BMI > 30. ❖ The mixture of its constituents forms a firm polysaccharide matrix capable to expand its volume in the stomach by absorbing water. ❖ Gel format
Slide 21: Our Sale Channels / Our Partners
OUR SALE CHANNELS OUR PARTNERS 21
Slide 22: Key Milestones
KEY MILESTONES 04 Uplisting to Nasdaq Stock Exchange Q1 2022 06 Launch of nutraceutical brand 01 Acquisition of 03 Launch of Mediterranation Decahedron Ltd in UK nutraceutical brand Q2 2022 Q2 2017 Sky Premium Life Q4 2019 2017 2018 2019 2022 07 Change of name from 02 Acquisition of 05 Strategic Cos
Slide 23: The Team
THE TEAM Greg Siokas Pavlos Ignatiades George Terzis Chief Executive Officer Chief Operating Officer Chief Financial Officer Greg Siokas has over 20 years of experience in the Pavlos Ignatiades has been a senior portfolio manager George Terzis oversees all Cosmos’ financial pharma industry. He has w
Slide 24: Management Commentary
MANAGEMENT COMMENTARY Greg Siokas, Chief Executive Officer of Cosmos Health, stated, "The slight decrease in our Consolidated Revenue reported in USD was mainly due to the high variation in FX differences of EUR and GBP to USD. In local currencies, we managed to increase our revenue in the third qua
Slide 25: Key Period Events
KEY PERIOD EVENTS Date Description Sep 15, 2022 Launch of Sky Premium Life nutritional supplements on eBay Austria and Germany. Jul 06, 2022 LIFE NLB acquisition of Bone Health Products portfolio “Bone Vio”, that target the gastrointestinal microbiome. Jul 12, 2022 Cosmos Health Subsidiary “Decahedr
Slide 26: Key Subsequent Events
KEY SUBSEQUENT EVENTS Date Description Cosmos Health Enters into a Warrant Exchange Agreement, Replacing Structured Warrants with Plain-Vanilla Warrants. The existing holders of Warrants issued as of February 28, 2022, will purchase an aggregate of 21,238,254 shares of Common Stock. They will exchan
Slide 27: Revenue & Gross Profit 2016–2021
REVENUE & GROSS PROFIT 2016 – 2021 Amounts in $ (‘000) 2016 2017 2018 2019 2020 2021 Revenue 6,755 30,013 37,084 39,676 55,406 56,240 Gross profit 601 1,956 2,409 3,662 8,060 8,330 % Gross profit margin 8.9% 6.5% 6.5% 9.2% 14.5% 14.8% Revenue & Gross profit margin 2016-2021 60.000 55.406 56.240 16,0
Slide 28: Third Quarter 2022 Performance
THIRD QUARTER 2022 PERFORMANCE Currency: $ ‘000 Q3 2022 Q3 2021 % Y-o-y 9m’ 2022 9m' 2021 % Y-o-y Revenue (in $ ‘000) & Adj EBITDA Margin (%) Revenue 12,016 13,595 -11.6% 38,296 40,061 -4.4% 20.000 16.178 20,0% Cogs (10,232) (11,250) -9.0% (32,775) (34,678) -5.5% Gross Profit 1,784 2,346 -23.9% 5,52
Slide 29: Balance Sheet 2021–Sept '22
BALANCE SHEET 2021- SEPT ‘22 Currency: $ ‘000 Sep 30, 2022 Dec 31, 2021 Var % Asset breakdown structure Sept’22 (in $ ‘000) Non-current assets 6,772 8,551 -20.8% 7.304; 16% 6.772; 15% Non-current assets 312; 0% Cash & cash equivalents 312 286 9.0% Cash & cash equivalents 3.983; 9% Accounts receivabl
Slide 30: Near-Term Catalysts
NEAR –TERM CATALYSTS Proven Revenue Growth Track Record Innovative Nutraceutical Products based on extended R&D efforts Well-positioned in the Marketplace with Globally Established Sales Networks Unique A to Z Business Model that distinguishes us from competitors Fully committed to our Shareholders
Slide 31: Thank You
THANK YOU 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 info@cosmoshold.com (US) +1 312 536 3102
Cosmos Health — Investor Presentation (December 2022) on 6ix